.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Teva
Farmers Insurance
Argus Health
Cerilliant
Colorcon
Mallinckrodt
Boehringer Ingelheim
Chubb
Deloitte

Generated: September 23, 2017

DrugPatentWatch Database Preview

TEMODAR Drug Profile

« Back to Dashboard

What is the patent landscape for Temodar, and what generic Temodar alternatives are available?

Temodar is a drug marketed by Merck Sharp Dohme and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-three patent family members in twenty-three countries.

The generic ingredient in TEMODAR is temozolomide. There are sixteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the temozolomide profile page.

Summary for Tradename: TEMODAR

Patents:3
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list85
Clinical Trials: see list81
Patent Applications: see list5,317
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TEMODAR at DailyMed

Pharmacology for Tradename: TEMODAR

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-001Aug 11, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-005Oct 19, 2006ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-002Aug 11, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-003Aug 11, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-004Aug 11, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-006Oct 19, 2006ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TEMODAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-001Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-006Oct 19, 2006► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-005Oct 19, 2006► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-003Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-002Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-004Aug 11, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TEMODAR

Drugname Dosage Strength RLD Submissiondate
temozolomideCapsules140 mg and 180 mgTemodar3/24/2008

Non-Orange Book Patents for Tradename: TEMODAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,674,790Processes of making and using pharmaceutical formulations of antineoplastic agents► Subscribe
8,076,335Processes of making pharmaceutical formulations of antineoplastic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TEMODAR

Country Document Number Estimated Expiration
European Patent Office1938798► Subscribe
Argentina064722► Subscribe
MexicoPA04008133► Subscribe
World Intellectual Property Organization (WIPO)03072082► Subscribe
Japan2008031186► Subscribe
Denmark1478339► Subscribe
Slovenia1478339► Subscribe
Australia2003213142► Subscribe
China1635871► Subscribe
Canada2476494► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Fish and Richardson
Mallinckrodt
Daiichi Sankyo
AstraZeneca
Johnson and Johnson
Harvard Business School
Argus Health
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot